1.01

0.98% -0.01

After Hours: 1.01

Cue Biopharma Inc (CUE)

Overview News Price History Option Chain Financials Discussions Forecast

Cue Biopharma Inc stock is traded at $1.01, with a volume of 596.61K. It is down -0.98% in the last 24 hours and down -7.34% over the past month. Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Previous Close:

$1.02

Open:

24h Volume:

596.61K

Relative Volume:

0.77

Market Cap:

$63.98M

Revenue:

$9.53M

Net Income/Loss:

$-44.61M

P/E Ratio:

-0.7953

EPS:

-1.27

Net Cash Flow:

$-38.32M

1W Performance:

+7.45%

1M Performance:

-7.34%

6M Performance:

-22.31%

1Y Performance:

-63.14%

1-Day Range:

$0.99

$1.09

1-Week Range:

$0.92

$1.22

52-Week Range:

$0.45

$3.20

Cue Biopharma Inc Stock (CUE) Company Profile

Name

Cue Biopharma Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617-949-2680

Address

40 GUEST STREET, BOSTON, MA

Employee

Twitter

@cuebiopharma

Next Earnings Date

2024-11-07

Latest SEC Filings

CUE's Discussions on Twitter

Compare CUE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CUE Cue Biopharma Inc	1.01	63.98M	9.53M	-44.61M	-38.32M	-0.91
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-24	Initiated	Jefferies	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform
Nov-21-22	Initiated	Piper Sandler	Overweight
Jan-13-22	Initiated	H.C. Wainwright	Buy
Jan-03-22	Initiated	Craig Hallum	Buy
Nov-24-20	Initiated	Berenberg	Buy
Apr-09-20	Initiated	Stifel	Buy
Jan-28-20	Initiated	BTIG Research	Buy
Jan-22-20	Initiated	JMP Securities	Mkt Outperform

View All

Cue Biopharma Inc Stock (CUE) Latest News

Dec 19, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia

Dec 19, 2024

Dec 18, 2024

Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India

Dec 18, 2024

Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com

Dec 18, 2024

Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat

Dec 18, 2024

Dec 16, 2024

Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat

Dec 16, 2024

Dec 13, 2024

Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com

Dec 13, 2024

Nov 29, 2024

Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 29, 2024

Cue Biopharma Grants 200,000 Share Option Award to New Development Chief - StockTitan

Nov 29, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 29, 2024

Strong week for Cue Biopharma (NASDAQ:CUE) shareholders doesn't alleviate pain of five-year loss - Simply Wall St

Nov 29, 2024

Nov 25, 2024

Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times

Nov 25, 2024

Cue Biopharma CEO to Present Clinical Updates at Piper Sandler Healthcare Conference | CUE Stock News - StockTitan

Nov 25, 2024